Extranodal NK/T-cell Lymphoma Clinical Trials

27 clinical trials for Extranodal NK/T-cell Lymphoma across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases — RECRUITING
• BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL — RECRUITING · PHASE3
• Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma — RECRUITING · PHASE1
• Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) — RECRUITING · PHASE1
• Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma — RECRUITING · PHASE2
• Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies — SUSPENDED · PHASE1
• Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma — NOT_YET_RECRUITING · PHASE3
• Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma — NOT_YET_RECRUITING · PHASE2
• A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type — ACTIVE_NOT_RECRUITING · PHASE2
• Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma — NOT_YET_RECRUITING · PHASE2
• Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms — COMPLETED · PHASE2
• Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL — OTHER · PHASE2
• B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma — COMPLETED · PHASE1
• Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia — OTHER · PHASE2
• Prognostic Nomogram of Extranodal NK/T-cell Lymphoma — OTHER
• Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL) — TERMINATED
• The Whole-course Management of Pegaspargase in ENKTL — OTHER · NA
• VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients — OTHER · PHASE2
• GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma — OTHER · PHASE2
• VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT) — OTHER · PHASE2
• Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma — OTHER · PHASE2
• Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL — OTHER · PHASE2
• Tofacitinib Combined With Chidamide in R/R ENKTCL — OTHER · PHASE2
• Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma — TERMINATED · PHASE2
• Retrospective Analysis of Skin/Soft Tissue Primary NK/T Cell Lymphoma — COMPLETED
• Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP — OTHER · PHASE3

Refine this search